Inflammatory Disease Treatment Composition Including Anti-Myosin Regulatory Light-Chain Polypeptide Antibody

Abstract

Provided is a means for inhibiting a function of CD69, whereby allowing suppression of an inflammatory response. That is, provided are: a composition for treating an inflammatory disease which includes an antibody that specifically recognizes a myosin regulatory light chain polypeptide (hereinafter abbreviated as Myl), preferably Myl9, Myl12a, and Myl12b, and inhibits a result of an effect of coexistence of Myl with CD69; a method of treating an inflammatory disease, including administering, to a subject diagnosed as having an inflammatory disease, a therapeutically effective amount of the antibody; and a method of identifying a compound that inhibits a result of an effect of coexistence of Myl with CD69, and a method of identifying a candidate compound for treating an inflammatory disease, including selecting a compound that inhibits the result.

1 - 12 . (canceled) 
     
     
         13 . A method of treating an inflammatory disease, comprising
 administering, to a subject diagnosed as having an inflammatory disease, an antibody that specifically recognizes myosin regulatory light chain polypeptide (Myl) and inhibits a result of an effect of coexistence of Myl with CD69, in an amount effective in treating the inflammatory disease.   
     
     
         14 . The method of treating an inflammatory disease according to  claim 13 , wherein the effect of coexistence of Myl with CD69 is a binding of Myl with CD69. 
     
     
         15 . The method of treating an inflammatory disease according to  claim 13 , wherein the Myl is any one or more selected from the group consisting of Myl9, Myl12a, and Myl12b. 
     
     
         16 . The method of treating an inflammatory disease according to  claim 13 , wherein the antibody is an antibody that specifically recognizes a partial amino acid sequence of Myl9, Myl12a, or Myl12b, and the partial amino acid sequence is the amino acid sequence of SEQ ID NO: 24. 
     
     
         17 . The method of treating an inflammatory disease according to  claim 13 , wherein the inflammatory disease is an airway inflammatory disease. 
     
     
         18 . The method of treating an inflammatory disease according to  claim 13 , wherein the inflammatory disease is an allergic airway inflammatory disease.